When was NanoCellect Biomedical founded?

NanoCellect Biomedical was founded in 2009 and raised its 1st funding round 1 year after it was founded.

Where is NanoCellect Biomedical located?

NanoCellect Biomedical is headquartered in San Diego, United States.

Who is the current CEO of NanoCellect Biomedical?

Chris Neary of NanoCellect Biomedical.

How many employees does NanoCellect Biomedical have?

As of Sep 30, 2026, the latest employee count at NanoCellect Biomedical is 21.

Is NanoCellect Biomedical a funded company?

NanoCellect Biomedical is a funded company, having raised a total of $78.1M across 23 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 31, 2010.

When was the latest funding round of NanoCellect Biomedical?

NanoCellect Biomedical's latest funding was a $***** Series D round on Jun 29, 2023, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.8B in funding in 2026 to date.

Where does NanoCellect Biomedical rank among its competitors?

NanoCellect Biomedical ranks 1st amongst 56 active competitors, of which 17 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Cytomos, which secured $6.32M in Nov, 2024.

Who are the top competitors of NanoCellect Biomedical?

NanoCellect Biomedical's top competitors include LumaCyte, Cell Microsystems and nanoMR. Among them, Cytomos secured the most recent funding round in November, 2024.

NanoCellect Biomedical - 2026 Company Profile, Team, Funding & Competitors

Company Details

NanoCellect Biomedical is a developer of molecular diagnostics, and improve personalized medicine. The company offers WOLF Cell Sorter, which uses a closed fluid-path microfluidic cartridge that enables cell sorting, and avoids biohazard and shear stress issues associated with traditional cell sorters. It claims that this technology sorts cells at the highest purity with almost no loss of viability. This technology has downstream applications of gene expression and sequencing. It also used in sorting rare cells such as circulating tumor cells (CTCs) from blood samples.

Website: nanocellect.com
Email ID: *****@nanocellect.com
Phone Number: +1 **********

Key Metrics

Founded Year

2009

Location

San Diego, United States

Stage

Series D

Total Funding

$78.1M in 23 rounds

Latest Funding Round

Series D, Jun 29, 2023, $*****

Investors

Warburg Pincus & 16 more

Ranked

1^st among 56 active competitors

Employee Count

21 as on Sep 30, 2026

Similar Companies

LumaCyte & 65 more

View NanoCellect Biomedical's full profile

NanoCellect Biomedical is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
NanoCellect Biomedical Inc CIN: 4873163 , United States, Active		-	84 (As on Dec 31, 2021)	-

NanoCellect Biomedical has raised a total funding of $78.1M over 23 rounds. Its first funding round was on Aug 31, 2010. NanoCellect Biomedical has 17 institutional investors.

Here is the list of recent funding rounds of NanoCellect Biomedical:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 29, 2023	2036133	Series D	4935291	9438496	8156230	2927907
Aug 24, 2022	6553694	Grant (prize money)	3654905	6154968	6224917	NIGMS
Aug 01, 2022	5250271	Grant (prize money)	7284096	7083568	1040896	HHS

Access funding benchmarks and valuations. Sign up today!

View details of NanoCellect Biomedical's funding rounds and investors

The founders of NanoCellect Biomedical is William Alaynick. Chris Neary is the CEO of NanoCellect Biomedical.

Here are the details of NanoCellect Biomedical's key team members:

William Alaynick: Co-Founder of NanoCellect Biomedical.
Chris Neary: CEO of NanoCellect Biomedical. They serve on the board of 1 company.

NanoCellect Biomedical's Board of Directors

NanoCellect Biomedical's board has 11 active members. William Alaynick, Jeremy Baker, Alexis Ji, Paul Conley, Kenneth Hood, Jack Ball, Jos? Morachis, Nate Heintzman, Chris Neary, Nicolas Barthelemy and Jose Morachis are independent board members.

Here is the list of NanoCellect Biomedical's board of directors:

Name	Type	Representing	Status	Duration
William Alaynick	Independent board member	-	Current	11y 0m
jpctacb	Independent board member	-	Current	7y 5m
qdizyip	Independent board member	-	Current	8y 8m
ccycyab	Independent board member	-	Current	3y 1m
imgkqbi	Independent board member	-	Current	6y 5m
wzhgfhc	Independent board member	-	Current	2y 8m
umwaufz	Independent board member	-	Current	1y 1m
vdicbkq	Independent board member	-	Current	7y 4m
enbbbwk	Independent board member	-	Current	2y 7m
ywiflbr	Independent board member	-	Current	2y 2m
nyfshmt	Independent board member	-	Current	8y 6m

View details of NanoCellect Biomedical's Founder profiles and Board Members

NanoCellect Biomedical's employee count trend

NanoCellect Biomedical has 21 employees as of Sep 26. Here is NanoCellect Biomedical's employee count trend over the years:

Employee count trend for NanoCellect Biomedical

Uncover NanoCellect Biomedical's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NanoCellect Biomedical include LumaCyte, Cell Microsystems and nanoMR. Here is the list of Top 10 competitors of NanoCellect Biomedical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	NanoCellect Biomedical 2009, San Diego (United States), Series D	Develops flow cytometry and cell sorting technology	$78.1M	Illumina Ventures, Vertical Venture Partners ... & 15 others	59/100
2nd	LumaCyte 2012, Charlottesville (United States), Series B	Provider of microfluidic and optics based instruments	$24.1M	Malvern Panalytical, Asahi Kasei	54/100
3rd	Cell Microsystems 2009, Durham (United States), Series B	Developer of a technology to isolate and recover single cells for molecular analysis	$19.1M	Telegraph Hill Partners, Telegraph Hill Partners ... & 4 others	51/100
4th	nanoMR 2006, Albuquerque (United States), Acquired	Developed the system for rapid isolation of rare cells	$25.5M	Dow Chemical Company, Sun Mountain Capital ... & 4 others	50/100
5th	ThinkCyte 2016, Bunkyo (Japan), Series C	Developer of cell sorting and single cell profiling platforms	$83.2M	SPARX Group, ITV & 20 others	49/100
6th	Single Cell Discoveries 2018, Utrecht (Netherlands), Unfunded	Provider of single-cell sequencing-based instrument and services	-	-	46/100
7th	Immunicon 1983, Bryn Athyn (United States), Acquired	Cell and molecular-based human diagnostic and life science research products for cancer disease management	$75.4M	Canaan, Wheatley Partners & 10 others	44/100
8th	Silicon Biosystems 1999, Bologna (Italy), Acquired	Developer of lab on a chip technologies for miniaturized cell-biology testing	$25.5M	Indaco Venture Partners, Innogest Capital ... & 1 others	44/100
9th	Cytomos 2012, Edinburgh (United Kingdom), Series A	POC cell sorter	$13.6M	Archangels, Scottish Enterprise & 21 others	44/100
10th	Cellular Highways 2016, Melbourn (United Kingdom), Acquired	Developer of cell sorting device	-	-	43/100